

Research

Insulin-like growth factor-1 protects ischemic murine myocardium from ischemia/reperfusion associated injury

Ehsan Y Davani¹, Zabrina Brumme², Gurpreet K Singhera³, H el ene CF C ot e⁴, P Richard Harrigan⁵ and Delbert R Dorscheid⁶

¹Graduate Student, University of British Columbia, McDonald Research Laboratories/iCAPTURE Center, St Paul's Hospital, Vancouver, British Columbia, Canada

²Graduate Student, University of British Columbia, BC Centre for Excellence in HIV/AIDS, St Paul's Hospital, Vancouver, British Columbia, Canada

³Post-Doctoral Fellow, University of British Columbia, McDonald Research Laboratories/iCAPTURE Center, St Paul's Hospital, Vancouver, British Columbia, Canada

⁴Post-Doctoral Fellow, University of British Columbia, BC Centre for Excellence in HIV/AIDS, St Paul's Hospital, Vancouver, British Columbia, Canada

⁵Clinical Assistant, Professor of Medicine, University of British Columbia, BC Centre for Excellence in HIV/AIDS, St Paul's Hospital, Vancouver, British Columbia, Canada

⁶Assistant Professor of Medicine, University of British Columbia, McDonald Research Laboratories/iCAPTURE Center, St Paul's Hospital, Vancouver, British Columbia, Canada

Corresponding author: Delbert R Dorscheid, ddorscheid@mrl.ubc.ca

Received: 26 April 2003

Revisions requested: 7 July 2003

Revisions received: 4 August 2003

Accepted: 18 August 2003

Published: 10 October 2003

Critical Care 2003, **7**:R176-R183 (DOI 10.1186/cc2375)

This article is online at <http://ccforum.com/content/7/6/R176>

  2003 Davani *et al.*, licensee BioMed Central Ltd (Print ISSN 1364-8535; Online ISSN 1466-609X). This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL.

Abstract

Introduction Ischemia/reperfusion occurs in myocardial infarction, cardiac dysfunction during sepsis, cardiac transplantation and coronary artery bypass grafting, and results in injury to the myocardium. Although reperfusion injury is related to the nature and duration of ischemia, it is also a separate entity that may jeopardize viable cells and ultimately may impair cardiac performance once ischemia is resolved and the organ heals.

Method The present study was conducted in an *ex vivo* murine model of myocardial ischemia/reperfusion injury. After 20 min of ischemia, isolated hearts were perfused for up to 2 hours with solution (modified Krebs's) only, solution plus insulin-like growth factor (IGF)-1, or solution plus tumor necrosis factor (TNF)- α . Cardiac contractility was monitored continuously during this period of reperfusion.

Results On the basis of histologic evidence, IGF-1 prevented reperfusion injury as compared with TNF- α ; TNF- α increased perivascular interstitial edema and disrupted tissue lattice integrity, whereas IGF-1 maintained myocardial cellular integrity and did not increase edema. Also, there was a significant reduction in detectable creatine phosphokinase in the perfusate from IGF-1 treated hearts. By recording transduced pressures generated during the cardiac cycle, reperfusion with IGF-1 was accompanied by markedly improved cardiac performance as compared with reperfusion with TNF- α or modified Krebs's solution only. The histologic and functional improvement generated by IGF-1 was characterized by maintenance of the ratio of mitochondrial to nuclear DNA within heart tissue.

Conclusion We conclude that IGF-1 protects ischemic myocardium from further reperfusion injury, and that this may involve mitochondria-dependent mechanisms.

Keywords apoptosis, mitochondrial DNA, myocardium, reperfusion injury, sepsis

ANOVA = analysis of variance; CPK = creatine phosphokinase; IGF = insulin-like growth factor; MK = modified Krebs's Henseleit working solution; mtDNA = mitochondrial DNA; nDNA = nuclear DNA; PCR = polymerase chain reaction; PI3 = phosphatidylinositol-3; $\Delta P_{\text{sys/dia}}$ = difference between *ex vivo* systolic and diastolic pressure; ROS = reactive oxygen species; TNF = tumor necrosis factor; VEGF = vascular endothelial growth factor.

Introduction

Cardiovascular diseases are among the leading causes of death in North America. The most important presentation of cardiovascular disease is ischemia, which leads to tissue hypoxia, cellular necrosis, apoptosis and, in severe situations, organ dysfunction. The main treatment for acute ischemic heart disease is early vascular reperfusion to restore balance to cardiac metabolic demands. Although reperfusion is the foundation of therapy, it may actually initiate further injury to the myocardium. Although the phenomenon of reperfusion injury is related to the duration of ischemia, it is a separate entity and may be more severe than ischemic injury alone [1,2]. Ischemia/reperfusion injury can be generated in various cardiovascular diseases/events or therapies, including myocardial infarction, cardiopulmonary bypass, coronary bypass grafting, heart transplantation, and coronary thrombolytic therapy. It has also been speculated that the mechanism of myocardial dysfunction during septic shock is related to segmental ischemia and reperfusion in the left ventricular wall, because the involvement of persistent global ischemia has been disproved [3,4].

Ischemia results from the absence of or sluggish blood flow in coronary vessels. This leads to a mismatch between cardiac metabolic supply and demand. Ischemia of short duration may contribute to 'stunned myocardium' without tissue injury, but prolonged ischemia results in a deficiency in energy supplies and waste removal, with eventual initiation of cellular necrosis and 'priming' of the myocytes for apoptosis [5]. Early restoration of blood flow or reperfusion reduces the extent of myocardium at risk for death from necrosis. However, in the presence of prolonged ischemia, reperfusion itself initiates mechanisms of injury that are fundamentally different and potentially more severe than those of ischemia.

Reperfusion injury is mediated by inflammation and characterized by the production of reactive oxygen species (ROS). Production of ROS may be initiated during the ischemic phase, generating 'primed' myocardium. ROS activate transcription factors, such as nuclear factor- κ B, both in cardiac myocytes and the endothelium; in turn, this initiates transcription of genes including those encoding adhesion molecules, cytokines, coagulation mediators, and proteolytic enzymes [6]. In coordination with the complement cascade, ROS can disrupt the integrity of both cardiac myocyte and endothelial cell membranes [7]. These events can change intracellular ion homeostasis, resulting in the accumulation of calcium and metabolic byproducts. These changes increase the activation of enzymes that are utilized in the processes of necrosis and apoptosis, and that alter mitochondrial function [8]. At the tissue level, this is manifested by interstitial edema and disruption of the tissue lattice. Concomitantly, neutrophils and other inflammatory cells migrate into the injured zone using adhesion molecules such as intercellular adhesion molecule-1 under the stimulation of secreted cytokines and chemotactic factors. Recruitment and infiltration of neu-

trophils into the injured tissue is accompanied by neutrophil degranulation and further injury to the border zone of viable cells. These late cellular events in the myocardium only occur after reperfusion [2,5,9,10].

Sustainable functioning of the myocardium is the central objective of therapeutic intervention in myocardial infarction. Cardiac function and contractility are closely related to cardiac metabolism and energy production. In cardiomyocytes energy production is related to the number of mitochondria, with these organelles occupying up to 40% of the cardiomyocyte cytoplasm. Hence, the total number of mitochondria in the myocardial tissue can be used as a measure of cardiomyocyte activity and health [11,12]. In HIV-infected patients with symptomatic hyperlactatemia receiving anti-retroviral therapy, Cote and coworkers [13] showed that the ratio of mitochondrial DNA (mtDNA) to nuclear DNA (nDNA) can be used as a marker of drug-induced mitochondrial toxicity. During the past century, there have been major improvements in the strategies used to protect myocardial tissue from ischemia/reperfusion injury [14–18]. However, the mechanism of ischemia/reperfusion injury remains unknown, and our abilities to treat and prevent it are therefore limited. Using methods similar to those used by Cote and coworkers [13], we investigated changes in heart mtDNA:nDNA ratio during myocardial ischemia and reperfusion phases, and compared these levels with additional measures of tissue injury.

New markers of myocardial injury may provide mechanistic insights and reveal therapeutic possibilities in reperfusion injury. Here, we propose a new method, using insulin-like growth factor (IGF)-1, of protecting cardiac tissue against ischemia/reperfusion injury in an *ex vivo* murine model. The mechanism underlying this protective effect remains unclear. However, the integrity of the myocardial tissue lattice was preserved and the development of interstitial edema in myocardial tissue was inhibited. These effects were correlated with improved perfusion pressure and left ventricular compliance. We also demonstrated that this IGF-1 mediated protection was accompanied by preservation of mtDNA content. The relevance of this finding to tissue function is discussed.

Methods

Ischemia/reperfusion model

C57B6 mice (Jackson Laboratories, Bar Harbor, ME, USA), weighing 25–30 g, were anesthetized using 3% isoflurane (Baxter, Toronto, Ontario, Canada) for 1 min and maintained with 1% isoflurane for 3–5 min during cardiac excision. To prevent coagulation in coronary vessels, 500 U heparin–sodium (Organon Teknika Inc., Toronto, Ontario, Canada) was injected intraperitoneally 10 min before induction of anesthesia. The heart was excised and assembled on a Langendorff apparatus and perfused with oxygenated (95% oxygen, 5% carbon dioxide), modified Krebs' Henseleit working solution (MK) at 37°C for 3–5 min [19–21] until monitoring revealed that the organ was stable. Transduced left

ventricular and aortic pressures, and heart rate were monitored continuously using Power lab/8sp detectors (AD Instruments Pty Ltd., Castle Hill, Australia). Retrograde perfusion was then stopped for 20 min to model global ischemia (a period of 20 min of ischemia was found to be optimal for the ischemic phase in this model). The ischemic hearts were then reperfused with MK solution alone, MK solution plus IGF-1 (10 ng/ml), or MK solution plus tumor necrosis factor (TNF)- α (10 ng/ml) for 1 or 2 hours. After completion of the reperfusion period, the hearts were divided into halves. One half was frozen using 2-methylbutane (Isopentane; MERK KgaA, Darmstadt, Germany) in liquid nitrogen for 80 s for eventual sectioning and/or DNA isolation. Paraffin embedding of the other half followed fixation of the sample in 10% formalin.

Histologic evaluation of different groups

Slides of paraffin embedded tissues from the apex to the basal portion of the hearts were prepared and stained with hematoxylin and eosin. Serial 400 \times magnified images were captured using a Nikon E600 microscope and Spot Advanced software (version 3.4.2; S. Leffler & Silicon Graphics Inc., Mountain View, CA, USA). Image Pro-Plus software (MediaCybernetics, Carlsbad, CA, USA) was used to evaluate the severity of interstitial edema around the perivascular spaces of coronary arteries and veins. Measures were taken in 10 sections from each of four hearts for all conditions and time points. The extent of interstitial edema was measured by selecting a circular area with a radius two times greater than the vascular space contained within the drawn circle. The total vascular and perivascular areas were measured. 'Nontissue' area was determined by color segmentation images constructed by Image Pro-Plus. Total interstitial edema was determined by subtracting the vascular area from the nontissue area and expressing this as a percentage of total perivascular area: percentage edema = $\frac{[\text{nontissue area} - \text{total vascular area}]}{\text{total perivascular area}} \times 100\%$.

Ventricular function assessment

Pressure generated during the cardiac cycle was obtained by transduction of the aortic cannula and recorded continuously during ischemia and reperfusion using a Power lab/8sp detector. Using Powerlab software, the difference between *ex vivo* systolic and diastolic pressure ($\Delta P_{\text{sys/dia}}$) at different time points was calculated to assess ventricular performance. Pressure measured during systole reflected contractility, and diastolic pressure drops reflected relaxation of the ventricle. Thus, greater $\Delta P_{\text{sys/dia}}$ values indicate better overall performance of the left ventricle.

Detection of creatine phosphokinase

A 1 ml sample of myocardial perfusate was collected every 15 min during the reperfusion phase. The samples were frozen in a mixture of ethanol and dry ice [22,23]. The level of creatine phosphokinase (CPK) was measured using Vitros CK slides (Ortho-Clinical Diagnostics, Rochester, NY, USA). Briefly, 11 μ l perfusate was deposited on the slide and evenly

distributed. Samples were incubated for 5 min at 37°C. After final interaction, leuco-dye is oxidized by hydrogen peroxide in the presence of peroxidase to form an insoluble dye. Reflection densities are monitored during incubation, and the rate of change in reflection density is then converted to enzyme activity by using 670 nm wavelength in the Vitros Chemistry 250 System.

Mitochondrial/nuclear DNA assay

Frozen hearts embedded in opaque tissue fixation material were thawed, cut into small pieces (approximately 3 mg), and then placed into lysis buffer. DNA was extracted using the Qiagen DNA isolation kit (Qiagen Canada, Qiagen Inc., Mississauga, Ontario, Canada), in accordance with the manufacturer's protocol. Extracts were then diluted 1:80 with buffer AE before performing the mtDNA assay, as reported previously [11,13,24] but modified for application in murine tissues as described below.

For each DNA extract, one murine nuclear gene (accessory subunit of the murine mitochondrial DNA polymerase γ [ASPG]; Genbank accession number AF177202) and one murine mitochondrial gene (cytochrome oxidase subunit 1 [COX], Genbank accession number AB042432) were quantified separately with real-time, quantitative PCR, using the Roche LightCycler (Roche Diagnostics, Indianapolis, IN, USA). For the mitochondrial (COX) gene, the forward primer mCOX1F (5'-TCGTTGATTATTCTCAACCAATCA-3') and the reverse primer mCOX2R (5'-GCCTCCAATTATTATTGGTATTACTATGA-3') were used. The oligonucleotides 3'-fluorescein-mCOXPR1 (5'-AACCAGGTGCACCTTTTAGGAGATGACC-F3') and 5'-LC Red 640 3'-phosphate-blocked-mCOXPR2 (5'-L-AATTTACAATGTTATCGTAACTGCCCATGC-P3') were used as hybridization probes. For the nuclear (ASPG) gene, the forward primer mASPG1F (5'-GGAGGAGGCACTTTCAGC-3') and the reverse primer mASPG2R (5'-GAAGACCTGCTCCCTGAACAC-3') were used. The oligonucleotides 5'-fluorescein-mASPGPR1 (GCGCTTTGGACCTTTGGG-TGTAG-F3') and mASPGPR2 (5'-L-GTTACGAAAGAACCT-AGCCTCACAGTGGT-P3') were used as hybridization probes. PCR reactions and amplification cycles were performed as described elsewhere [13].

A standard curve consisting of serially diluted mouse DNA (30 000, 6000, 1200, 240 and 48 nuclear genome equivalents) were included in each run. The same standard curve was used to quantify both the nuclear (ASPG) and the mitochondrial (COX) genes. mtDNA and nDNA genes were assayed in duplicate. Results of the quantitative PCR assay were expressed as the ratio of the mean value of the duplicate mtDNA measurements to the mean value of duplicate nDNA measurements. As a further quality control, a mouse DNA extract with a mtDNA:nDNA ratio known to be high, and an extract with a mtDNA:nDNA ratio known to be low were included in every run. Repeat sample and intrasample variations were under 5%.

Statistical analysis

Values are expressed as mean \pm standard error. $P < 0.05$ was considered statistically significant.

Results


Perivascular interstitial edema and tissue lattice integrity

The cellular integrity of the myocardium was well preserved in the tissue of hearts reperfused with IGF-1 (Fig. 1). The area of interstitial edema in hearts treated with IGF-1 plus MK was $21 \pm 4\%$, as compared with $34 \pm 6\%$ and $49 \pm 5\%$ for reperfusion with MK only and MK plus TNF- α , respectively. Representative tissue histology images are presented in Fig. 1 and were similar throughout the four hearts and in all conditions. Additional histology observations included an increased number of shrunken, contracted myocytes with dense pyknotic nuclei with MK plus TNF- α reperfusion as compared with perfusate containing IGF-1. Using single factor analysis of variance (ANOVA), the differences in percentage edema between groups were statistically significant ($P < 0.05$).

Insulin-like growth factor-1: improvement in myocardial performance during reperfusion

Cardiac performance was determined by calculating the pressure difference between systole and diastole (i.e. $\Delta P_{\text{sys/dia}}$) at set time points. The systolic and diastolic pressures were determined by taking the average values from a window around the respective time points. Performance is then a measure of both contractility (stroke volume and force of left ventricular contraction, manifesting as systolic pressure) and diastolic function, or relaxation of the left ventricle (a reduction in diastolic pressures). Improved performance is manifested by a widening in $\Delta P_{\text{sys/dia}}$. Pressure monitoring demonstrated that cardiac performance increased from 0 to 40 min of reperfusion for all conditions (Fig. 2). After 40 min of reperfusion, cardiac performance arrived at a plateau and became negative for the remaining minutes for the MK alone and the MK plus TNF- α reperfusion. With reperfusion with MK plus TNF- α the difference between systolic and diastolic pressure ($\Delta P_{\text{sys/dia}}$) initially increased to 6.8 ± 0.7 mmHg as compared with reperfusion with MK alone (5.1 ± 0.6 mmHg). However, reperfusion with IGF-1 generated a $\Delta P_{\text{sys/dia}}$ that was significantly greater (13.8 ± 1.2 mmHg) than that with TNF- α (6.8 ± 0.7 mmHg) by 20 min. This gain in cardiac performance was maintained up to 120 min of reperfusion with IGF-1. The enhanced performance was reflected in improvements in both systolic and diastolic pressures. The late descent in slope at 120 min of reperfusion with IGF-1 was similar to that occurring with reperfusion with MK alone and with MK plus TNF- α , but may relate to *ex vivo* conditions other than the ischemia time and the reperfusion solution. A paired, two sample *t*-test for means between groups demonstrated a statistically significant difference between IGF-1 and MK alone and MK plus TNF- α ($P < 0.005$).

Figure 1



Representative images of hematoxylin and eosin stained sections from murine hearts subjected to ischemia/reperfusion. Images are of control, ischemia without reperfusion, and reperfusion with modified Krebs Henseleit working solution (MK) alone, MK plus tumour necrosis factor (TNF)- α , and MK plus insulin-like growth factor (IGF)-1, both at 1 and 2 hours. Note the preservation of cellular and structural elements and the lack of interstitial edema in the IGF-1 reperfused heart. Magnification for all images: 400 \times .

Low creatine phosphokinase level in insulin-like growth factor-1 treated hearts


Collected perfusate from hearts treated with IGF-1, at all reperfusion time points, contained significantly lower quantities of detectable CPK (34.6 U/l) than did perfusate from TNF- α treated hearts (113.6 U/l). This is shown as an average for all time points in Fig. 3. Single factor ANOVA revealed a statistically significant difference between groups ($P < 0.005$).

Ratio of mitochondrial to nuclear DNA

IGF-1 maintained or improved the mtDNA:nDNA ratio during reperfusion of ischemic myocardium as compared with control reperfusion with MK alone. There was a significant difference between all test groups (baseline, ischemia, reperfusion with MK alone, and reperfusion with MK plus IGF-1) in the determined mtDNA:nDNA ratio ($P < 0.05$, by ANOVA). Based on previous work, it was thought useful to test the utility of mtDNA:nDNA ratio to assess the 'cellular health' of ischemic and reperfused myocardial tissues [11,12]. How IGF-1 preserves mtDNA:nDNA ratio and if this also means intact oxidative mitochondrial function that promotes cellular viability remains to be investigated.


We found that IGF-1 appeared to protect heart tissue against a reduction in the mtDNA:nDNA ratio, which was accompanied by improved histologic grading and improved organ function in terms of contractility. A reduction in this ratio may represent either necrosis of at-risk tissue or a reduction in mitochondrial number (mitoptosis) after the initial stimulus

Figure 2




Determination of cardiac performance. **(a)** Tracings from continuous monitor recordings obtained during ischemia and reperfusion. Each tracing demonstrates the aortic and left ventricular transduced pressure over time. The mid-point in the tracing is at 20 min of reperfusion. The conditions are modified modified Kreb's Henseleit working solution (MK) alone, MK plus tumour necrosis factor (TNF- α), and MK plus insulin-like growth factor (IGF-1). **(b)** Determination of cardiac performance is as described in the Methods section (see text) and includes calculation of the pressure gradient between the systolic and diastolic pressure transductions from the aorta and left ventricle. As demonstrated, reperfusion with IGF-1 generates a significant improvement in cardiac performance at all time points. Analysis demonstrated a significant difference between reperfusion with IGF-1 plus MK as compared with MK alone and MK plus TNF- α ($P < 0.005$).

Figure 3



Measured creatine phosphokinase in perfusate from reperfused murine hearts. Hearts were prepared for Langendorf *ex vivo* reperfusion and perfused until the monitored heart rate and pressure were stable (approximately 3–5 min); then they were subjected to 20 min of ischemia followed by reperfusion. Perfusate solution was collected (approximately 1 ml/4 min) around each time point for determination of CPK activity. For all time points, tumour necrosis factor (TNF- α) reperfusion generated a significant elevation in the detectable amount of CPK activity relative to that detected with insulin-like growth factor (IGF)-1 reperfusion ($P < 0.005$, by analysis of variance).

Figure 4



Determination of mitochondrial DNA (mtDNA) : nuclear DNA (nDNA) ratio. The mtDNA : nDNA ratio was determined for the following conditions: control; ischemia without reperfusion; modified Kreb's Henseleit working solution (MK) alone for 1 hour; MK alone for 2 hours; MK plus insulin-like growth factor (IGF)-1 for 1 hour; and MK with insulin-like growth factor (IGF)-1 for 2 hours. The number within each histogram represents the number of hearts processed for that condition. The values for mtDNA : nDNA ratio in the controls, ischemic myocardial tissue, and either reperfusion group (MK or IGF-1) were significantly different from each other ($P < 0.05$).

lized a cell-free perfusate, the mtDNA : nDNA ratio is not confounded by potential contributions from immune cells – a point that has been raised as a possible explanation for changes in mtDNA : nDNA ratio.

Discussion

Despite a range of clinical interventions, our ability to prevent reperfusion injury after disruption of blood flow to vascular

(ischemia) followed by subsequent reperfusion (Fig. 4). Such a reduction was noted with reperfusion with MK alone after the initial increase in mtDNA : nDNA ratio that occurred after ischemia alone without reperfusion. Because this model uti-

beds remains disappointing. An appreciation of the mechanism of ischemia/reperfusion injury is central to development of better treatments. In the present study we demonstrated that IGF-1 can lessen reperfusion injury following an initial ischemic insult.

This effect of IGF-1 on the ischemic myocardium was supported by histologic evidence of improved tissue and cellular integrity, including markedly less interstitial edema around the perivascular spaces. In this model, ischemic myocardium treated with IGF-1 had significantly lesser amounts of detectable CPK than did myocardium treated with TNF- α , suggesting reduced cellular injury. This is also consistent with the cardiac performance and left ventricular contractility of IGF-1 treated hearts, that exhibited a greater $\Delta P_{\text{sys/dia}}$. It should be noted that the detectable CPK levels would not be above the normal range as determined for human whole blood samples. However, there was considerable histologic evidence of tissue damage in the TNF- α treated hearts, suggesting the relative insensitivity of CPK in detecting lesser myocardial injuries. A more sensitive marker would be valuable not only for studying the mechanism that underlies reperfusion injury but also for evaluating the efficacy of therapeutic interventions. This is particularly true when one considers the segmental and intermittent ischemic/reperfusion zones that characterize dysfunctional myocardium in sepsis. The initial improvement in contractility, observed under all conditions of reperfusion, was probably the result of a new supply of nutrients after the ischemic period, including oxygen. The addition of IGF-1 significantly augmented this improvement in left ventricular pressure generation and relaxation (thus increasing $\Delta P_{\text{sys/dia}}$). This improvement was maintained throughout the period of reperfusion.

Myocardial performance at the cellular level is associated with the number or functional capacity of mitochondria. To investigate indirectly whether mitochondrial function may represent a marker of this beneficial effect of IGF-1, we determined the mtDNA:nDNA ratio in relation to myocardial function. Although not appreciated clinically, ischemia and reperfusion are two distinct periods [10,14,16,25,26]. The ischemic period has been described as 'priming' cardiac myocytes for either necrotic or apoptotic death. A marked increase in mtDNA:nDNA ratio was detected in the ischemic myocardium relative to baseline control levels. Apoptosis has been found to be an event that requires energy [27,28]. Whether this increased mtDNA:nDNA ratio indicates an increase in the number of mitochondria per cell or an increase in the genome copy number per mitochondria remains to be determined.

Myocardial reperfusion injury, as a separate event, can increase the extent of injury beyond that caused by ischemia alone. It has been shown that modification of solutions or other conditions during the reperfusion phase can alter the extent of cellular and functional damage to the myocardium.

We determined that the nature of the reperfusate can affect mtDNA:nDNA ratio. Reperfusion with MK alone resulted in a reduction in mtDNA:nDNA ratio toward baseline values. This may reflect either mitochondrial mitoptosis in damaged and 'primed' tissues, or necrotic loss of similar cells that were 'primed', resulting in elevated mtDNA:nDNA ratio after ischemia. The net effect would be that the remaining tissue is spared and should reflect baseline tissue. However, a mtDNA:nDNA ratio that does not differ from baseline does not indicate that the tissue is working normally. In fact, histology and contractility determinations demonstrated that the heart had sustained significant tissue damage and was dysfunctional after MK reperfusion. With IGF-1 reperfusion this reduction in mtDNA:nDNA ratio was prevented, suggesting that the extent of injury is not associated with elevated mtDNA:nDNA ratio alone. In fact, after ischemia/reperfusion, it was found that a normal mtDNA:nDNA ratio early after reperfusion predicted significant tissue injury. The patterns of mtDNA:nDNA ratio, as seen in this model, may prove useful in future investigations of possible mitochondria-related mechanisms of reperfusion injury.

IGF-1 can affect cardiomyocyte contractility through its receptor – a heterotetrameric protein with intracellular tyrosine kinase activity [29]. Downstream signals after receptor activation include Shc, Crk and phospholipase C, and activation of phosphatidylinositol-3 (PI3) kinase. Guse and coworkers [30] demonstrated that IGF-1 can increase PI3 levels in rat cardiomyocytes. Through its action on PI3 kinase, IGF-1 can affect both contractility [31] and apoptosis [32]. The action of IGF-1, as demonstrated in our myocardial ischemia/reperfusion model, may occur via PI3 kinase and/or effects on mitochondria. Increases in cardiomyocyte calcium levels and cardiomyocyte sensitivity to calcium [33] have been demonstrated to effect cardiac performance. Alteration in calcium metabolism may interfere with the action of calcium because the filamentous network of cardiomyocytes and their contractile properties are extremely sensitive to even small fluctuations in calcium ion concentration [34].

A similar result to that presented here for IGF-1 in myocardial ischemia/reperfusion has been demonstrated for vascular endothelial growth factor (VEGF), suggesting that a final common 'protective' pathway may exist [35]. Anwar and coworkers [36] showed that TNF- α decreased IGF-1 mRNA and increased IGF-1 binding protein-3 mRNA expression in vascular smooth muscle cells. These actions of TNF- α effectively reduced free IGF-1 levels and activity, and promoted endothelial instability. Infusion of a modified IGF-1 reduced the TNF- α induced apoptosis. An interaction between VEGF and IGF-1 was characterized in retinal neovascularization in diabetic patients [37]. The authors of that report described common mitogen-activated protein kinase 44/42 pathways that may be related to the mitogenic effect of those two molecules. However, the short time to effect for both IGF-1 and VEGF in myocardial ischemia/reperfusion models is most

Key messages

- In an *ex vivo* model of myocardial ischemia and reperfusion, IGF-1 protects against reperfusion-associated injury and improves cardiac performance
- This protective effect correlates to mtDNA:nDNA ratio that was elevated with respect to baseline and may represent a marker for the preservation of mitochondrial function
- This study provides new insight into ischemia reperfusion and possible mechanisms and treatment for the tissue injury and organ dysfunction that is associated with this process

probable through the Akt pathway [38,39]. Akt activation can improve contractility through PI3 kinase signaling, and is also an initiator of protein kinase C activation upstream. Protein kinase C plays an important role in cardiac function, calcium metabolism, and contractility. Michell and coworkers [38] showed that IGF-1 and VEGF both stimulate nitric oxide production from endothelial cells and that inhibition of PI3 kinase by wortmannin and LY29004 decreases nitric oxide production and reduces cardiac function. Akt signaling has also been demonstrated to prevent apoptosis. Whether this pathway alters the expression of Bcl-2 family members by IGF-1 exposure remains unknown.

It has been shown that IGF-1 can protect myocardium and other tissues against apoptosis in various animal models [40–42]. IGF-1 may also improve cardiac function in diabetic patients [41–45] and rat models of myocardial infarction and reperfusion [26]. It has been shown that IGF-1 can protect myocardium by regulating changes in proapoptotic and/or antiapoptotic molecules such as Bcl-2, Bcl-X_L and Bax. These are all related to the mitochondrial apoptotic pathway and mitochondrial energetics [26]. This may explain, in part, how IGF-1 protects myocardium even in the later phase of reperfusion injury.

In an *ex vivo* model of myocardial ischemia and reperfusion we demonstrated that IGF-1 protects against reperfusion associated injury. We found this protective effect of IGF-1 to be correlated with elevated mtDNA:nDNA relative to baseline, and this may represent a marker of preservation of mitochondrial function. This study provides new insights into ischemia/reperfusion, and suggests possible mechanisms and treatments for the tissue injury and organ dysfunction associated with this process. The eventual benefit of this to our understanding of myocardial dysfunction in sepsis awaits further study.

Competing interests

R182 None declared.

Acknowledgements

Grant support for this project was provided by the Heart & Stroke Foundation of British Columbia and Yukon. DRD is a recipient of a Parker B Francis Fellowship in Pulmonary Research and a Michael Smith Foundation for Health Research Scholar Award. The authors thank Yijin Wang and Katherine Craig, MD, for their technical expertise and contributions in the preparation of this manuscript.

References

1. Ganz W: **Direct demonstration in dogs of the absence of lethal reperfusion injury.** *J Thromb Thrombolysis* 1997, **4**:105-107.
2. Schaper W, Schaper J: **Reperfusion injury: an opinionated view.** *J Thromb Thrombolysis* 1997, **4**:113-116.
3. Dhainaut JF, Huyghebaert MF, Monsallier JF, Lefevre G, Dall'Ava-Santucci J, Brunet F, Villemant D, Carli A, Raichvarg D: **Coronary hemodynamics and myocardial metabolism of lactate, free fatty acids, glucose, and ketones in patients with septic shock.** *Circulation* 1987, **75**:533-541.
4. Cunnion RE, Schaer GL, Parker MM, Natanson C, Parrillo JE: **The coronary circulation in human septic shock.** *Circulation* 1986, **73**:637-644.
5. Gross GJ, Kersten JR, Wartier DC: **Mechanisms of postischemic contractile dysfunction.** *Ann Thorac Surg* 1999, **68**:1898-1904.
6. Kis A, Yellon DM, Baxter GF: **Role of nuclear factor-kappaB activation in acute ischaemia-reperfusion injury in myocardium.** *Br J Pharmacol* 2003, **138**:894-900.
7. Pietri S, Mercier A, Mathieu C, Caffaratti S, Culcasi M: **Hemodynamic and metabolic effects of the beta-phosphorylated nitroxide 2-diethoxyphosphoryl-2,5,5-trimethylpyrrolidinoxyl during myocardial ischemia and reperfusion.** *Free Radic Biol Med* 2003, **34**:1167-1177.
8. Park JL, Lucchesi BR: **Mechanisms of myocardial reperfusion injury.** *Ann Thorac Surg* 1999, **68**:1905-1912.
9. Kukreja RC, Janin Y: **Reperfusion Injury: Basic concepts and protection strategies.** *J Thromb Thrombolysis* 1997, **4**:7-24.
10. Laude K, Thuillez C, Richard V: **Coronary endothelial dysfunction after ischemia-reperfusion: mechanisms and possibilities for protection [in French].** *Therapie* 2001, **56**:589-593.
11. Benbrik E, Chariot P, Bonavaud S, Ammi-Said M, Frisdal E, Rey C, Gherardi R, Barlovatz-Meimon G: **Cellular and mitochondrial toxicity of zidovudine (AZT), didanosine (ddI) and zalcitabine (ddC) on cultured human muscle cells.** *J Neurol Sci* 1997, **149**:19-25.
12. Mansouri A, Demeilliers C, Amsellem S, Pessayre D, Fromenty B: **Acute ethanol administration oxidatively damages and depletes mitochondrial DNA in mouse liver, brain, heart, and skeletal muscles: protective effects of antioxidants.** *J Pharmacol Exp Ther* 2001, **298**:737-743.
13. Cote HC, Brumme ZL, Craib KJ, Alexander CS, Wynhoven B, Ting L, Wong H, Harris M, Harrigan PR, O'Shaughnessy MV, Montaner JS: **Changes in mitochondrial DNA as a marker of nucleoside toxicity in HIV-infected patients.** *N Engl J Med* 2002, **346**:811-820.
14. Boyle EM Jr, Cauty TG Jr, Morgan EN, Yun W, Pohlman TH, Verrier ED: **Treating myocardial ischemia-reperfusion injury by targeting endothelial cell transcription.** *Ann Thorac Surg* 1999, **68**:1949-1953.
15. Condorelli G, Drusco A, Stassi G, Bellacosa A, Roncarati R, Iaccarino G, Russo MA, Gu Y, Dalton N, Chung C, Latronico MV, Napoli C, Sadoshima J, Croce CM, Ross J Jr: **Akt induces enhanced myocardial contractility and cell size in vivo in transgenic mice.** *Proc Natl Acad Sci USA* 2002, **99**:12333-12338.
16. Lozza G, Conti A, Ongini E, Monopoli A: **Cardioprotective effects of adenosine A1 and A2A receptor agonists in the isolated rat heart.** *Pharmacol Res* 1997, **35**:57-64.
17. Schlensak C, Doenst T, Kobba J, Beyersdorf F: **Protection of acutely ischemic myocardium by controlled reperfusion.** *Ann Thorac Surg* 1999, **68**:1967-1970.
18. Todd J, Zhao ZQ, Williams MW, Sato H, Van Wylene DG, Vinten-Johansen J: **Intravascular adenosine at reperfusion reduces infarct size and neutrophil adherence.** *Ann Thorac Surg* 1996, **62**:1364-1372.
19. Headrick JP, Peart J, Hack B, Flood A, Matherne GP: **Functional properties and responses to ischaemia-reperfusion in Langendorff perfused mouse heart.** *Exp Physiol* 2001, **86**:703-716.

20. Sumeray MS, Yellon DM: **Characterisation and validation of a murine model of global ischaemia-reperfusion injury.** *Mol Cell Biochem* 1998, **186**:61-68.
21. Wang QD, Swardh A, Sjoquist PO: **Relationship between ischaemic time and ischaemia/reperfusion injury in isolated Langendorff-perfused mouse hearts.** *Acta Physiol Scand* 2001, **171**:123-128.
22. O'Brien PJ, Dameron GW, Beck ML, Kang YJ, Erickson BK, Di Battista TH, Miller KE, Jackson KN, Mittelstadt S: **Cardiac troponin T is a sensitive, specific biomarker of cardiac injury in laboratory animals.** *Lab Anim Sci* 1997, **47**:486-495.
23. Apple FS: **The specificity of biochemical markers of cardiac damage: a problem solved.** *Clin Chem Lab Med* 1999, **37**: 1085-1089.
24. Birkus G, Hitchcock MJ, Cihlar T: **Assessment of mitochondrial toxicity in human cells treated with tenofovir: comparison with other nucleoside reverse transcriptase inhibitors.** *Antimicrob Agents Chemother* 2002, **46**:716-723.
25. Flood AJ, Willems L, Headrick JP: **Coronary function and adenosine receptor-mediated responses in ischemic-reperfused mouse heart.** *Cardiovasc Res* 2002, **55**:161-170.
26. Yamamura T, Otani H, Nakao Y, Hattori R, Osako M, Imamura H: **IGF-I differentially regulates Bcl-xL and Bax and confers myocardial protection in the rat heart.** *Am J Physiol Heart Circ Physiol* 2001, **280**:H1191-H1200.
27. Kerr JF, Wyllie AH, Currie AR: **Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics.** *Br J Cancer* 1972, **26**:239-257.
28. Kang PM, Haunstetter A, Aoki H, Usheva A, Izumo S: **Morphological and molecular characterization of adult cardiomyocyte apoptosis during hypoxia and reoxygenation.** *Circ Res* 2000, **87**:118-125.
29. Wang L, Ma W, Markovich R, Chen JW, Wang PH: **Regulation of cardiomyocyte apoptotic signaling by insulin-like growth factor I.** *Circ Res* 1998, **83**:516-522.
30. Guse AH, Kiess W, Funk B, Kessler U, Berg I, Gercken G: **Identification and characterization of insulin-like growth factor receptors on adult rat cardiac myocytes: linkage to inositol 1,4,5-trisphosphate formation.** *Endocrinology* 1992, **130**:145-151.
31. Cittadini A, Ishiguro Y, Stromer H, Spindler M, Moses AC, Clark R, Douglas PS, Ingwall JS, Morgan JP: **Insulin-like growth factor-1 but not growth hormone augments mammalian myocardial contractility by sensitizing the myofilament to Ca²⁺ through a wortmannin-sensitive pathway: studies in rat and ferret isolated muscles.** *Circ Res* 1998, **83**:50-59.
32. Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y, Greenberg ME: **Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery.** *Cell* 1997, **91**:231-241.
33. Ren J, Walsh MF, Hamaty M, Sowers JR, Brown RA: **Altered inotropic response to IGF-I in diabetic rat heart: influence of intracellular Ca²⁺ and NO.** *Am J Physiol* 1998, **275**:H823-H830.
34. Brandes R, Bers DM: **Intracellular Ca²⁺ increases the mitochondrial NADH concentration during elevated work in intact cardiac muscle.** *Circ Res* 1997, **80**:82-87.
35. Luo Z, Diaco M, Murohara T, Ferrara N, Isner JM, Symes JF: **Vascular endothelial growth factor attenuates myocardial ischemia-reperfusion injury.** *Ann Thorac Surg* 1997, **64**:993-998.
36. Anwar A, Zahid AA, Scheidegger KJ, Brink M, Delafontaine P: **Tumor necrosis factor-alpha regulates insulin-like growth factor-1 and insulin-like growth factor binding protein-3 expression in vascular smooth muscle.** *Circulation* 2002, **105**: 1220-1225.
37. Smith LE, Shen W, Perruzzi C, Soker S, Kinose F, Xu X, Robinson G, Driver S, Bischoff J, Zhang B, Schaeffer JM, Senger DR: **Regulation of vascular endothelial growth factor-dependent retinal neovascularization by insulin-like growth factor-1 receptor.** *Nat Med* 1999, **5**:1390-1395.
38. Michell BJ, Griffiths JE, Mitchelhill KI, Rodriguez-Crespo I, Tiganis T, Bozinovski S, de Montellano PR, Kemp BE, Pearson RB: **The Akt kinase signals directly to endothelial nitric oxide synthase.** *Curr Biol* 1999, **9**:845-848.
39. Fulton D, Gratton JP, McCabe TJ, Fontana J, Fujio Y, Walsh K, Franke TF, Papapetropoulos A, Sessa WC: **Regulation of endothelium-derived nitric oxide production by the protein kinase Akt.** *Nature* 1999, **399**:597-601.
40. Reeves I, Aribat T, Laramee P, Jasmin G, Brazeau P: **Age-related serum levels of insulin-like growth factor-I, -II and IGF-binding protein-3 following myocardial infarction.** *Growth Horm IGF Res* 2000, **10**:78-84.
41. Norby FL, Wold LE, Duan J, Hintz KK, Ren J: **IGF-I attenuates diabetes-induced cardiac contractile dysfunction in ventricular myocytes.** *Am J Physiol Endocrinol Metab* 2002, **283**:E658-E666.
42. Guan J, Bennet L, George S, Wu D, Waldvogel HJ, Gluckman PD, Faull RL, Crosier PS, Gunn AJ: **Insulin-like growth factor-1 reduces postischemic white matter injury in fetal sheep.** *J Cereb Blood Flow Metab* 2001, **21**:493-502.
43. Boes M, Dake BL, Booth BA, Sandra A, Bateman M, Knudtson KL, Bar RS: **IGF-I and IGFBP-3 transport in the rat heart.** *Am J Physiol Endocrinol Metab* 2003, **284**:E237-E239.
44. Nakao Y, Otani H, Yamamura T, Hattori R, Osako M, Imamura H: **Insulin-like growth factor 1 prevents neuronal cell death and paraplegia in the rabbit model of spinal cord ischemia.** *J Thorac Cardiovasc Surg* 2001, **122**:136-143.
45. von Lewinski D, Voss K, Hulsmann S, Kogler H, Pieske B: **Insulin-like growth factor-1 exerts Ca²⁺-dependent positive inotropic effects in failing human myocardium.** *Circ Res* 2003, **92**:169-176.